ERCC1在胃癌组织中的表达及其对含铂类辅助化疗疗效的影响

ERCC1 expression in gastric carcinoma tissue and its influence on efficacy of adjuvant chemotherapeutic regimens containing platinum

关键词:  胃癌  ERCC1  预后

Key words:  gastric cancer  ERCC1  prognosis

摘要:

目的　探讨ERCC1在胃癌组织中的表达及对含铂类辅助化疗患者无病生存期（DFS）和总生存期（OS）的影响。方法　收集34例胃癌根治术后患者的临床及病理资料，应用免疫组织化学方法检测ERCC1在胃癌组织中的表达，采用SPSS18.0软件进行统计学分析， χ2检验分析ERCC1表达与临床特征的相关性， Kaplan-Meier方法分析ERCC1表达对含铂类辅助化疗患者生存期的影响。结果　 ERCC1表达与肿瘤发病部位、大小、浸润深度、组织学类型、淋巴结转移、TNM分期无关。ERCC1表达阳性者DFS 11个月，中位OS 20个月；ERCC1阴性表达者DFS14.5个月，中位OS为23.5个月。ERCC1阳性表达患者与阴性表达患者比较，DFS差异无显著性意义（P>0.05），中位OS差异有显著性意义（P<0.05）。结论　胃癌ERCC1的表达与临床特征不相关，可以作为胃癌根治术后接受含铂类辅助化疗疗效的预测指标。

Abstract:

Objective 　To investigate the expression of ERCC1 in gastric cancer tissue and its influence on disease-free survival (DFS) and overall survival (OS) of the patients who underwent adjuvant chemotherapies with regimen containing platinum. 　Methods　Thirty-four patients with gastric cancer post to radical operation were included into this retrospective study, ERCC1 expression in tumor were detected with immunohistochemistry (IHC), and chi-square-test was used to analyze the correlation between ERCC1 expression and clinical features. Kaplan-Meier analysis was used to analyze the influence of ERCC1 expression on survivals of patients treated with adjuvant chemotherapy with regimens containing platinum. SPSS18.0 was used for statistics. 　Results 　ERCC1 expression was found not correlated to features of the primary tumor such as location, size, infiltration depth or histology, lymph node metastasis, or TNM stage. DFS and median OS were observed to be 11 and 20 months respectively in patients positive in ERCC1 expression, in contrast to 14.5 and 23.5 months in those negative. Compared with ERCC1 positive patients, the negatives had the significant difference in median OS (P<0.05) but not in DFS (P>0.05). 　Conclusion 　ERCC1expression dose not correlate to clinical features in gastric cancer patients, but it can be used as a marker predicting efficacy for patients with gastric cancer post to operation treated with adjuvant regimens containing the platinum.